NZ519990A - Brain, spinal and nerve injury treatment - Google Patents
Brain, spinal and nerve injury treatmentInfo
- Publication number
- NZ519990A NZ519990A NZ519990A NZ51999001A NZ519990A NZ 519990 A NZ519990 A NZ 519990A NZ 519990 A NZ519990 A NZ 519990A NZ 51999001 A NZ51999001 A NZ 51999001A NZ 519990 A NZ519990 A NZ 519990A
- Authority
- NZ
- New Zealand
- Prior art keywords
- formulation
- magnesium
- substance
- receptor antagonist
- brain
- Prior art date
Links
- 208000029028 brain injury Diseases 0.000 title claims abstract description 36
- 210000004556 brain Anatomy 0.000 title claims abstract description 30
- 238000011282 treatment Methods 0.000 title claims abstract description 14
- 208000028389 Nerve injury Diseases 0.000 title claims abstract description 8
- 230000008764 nerve damage Effects 0.000 title claims abstract description 8
- 208000020339 Spinal injury Diseases 0.000 title description 3
- 239000003890 substance P antagonist Substances 0.000 claims abstract description 23
- 239000002464 receptor antagonist Substances 0.000 claims abstract description 18
- 229940044551 receptor antagonist Drugs 0.000 claims abstract description 18
- 150000002681 magnesium compounds Chemical class 0.000 claims abstract description 15
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims abstract description 13
- 102100037346 Substance-P receptor Human genes 0.000 claims abstract description 12
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 claims abstract description 5
- 102100037342 Substance-K receptor Human genes 0.000 claims abstract description 5
- 239000007972 injectable composition Substances 0.000 claims abstract description 5
- 210000000278 spinal cord Anatomy 0.000 claims abstract description 5
- 208000020431 spinal cord injury Diseases 0.000 claims abstract description 5
- 238000009472 formulation Methods 0.000 claims description 32
- 208000014674 injury Diseases 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- 208000027418 Wounds and injury Diseases 0.000 claims description 30
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 29
- 230000006378 damage Effects 0.000 claims description 29
- 239000011777 magnesium Substances 0.000 claims description 29
- 229910052749 magnesium Inorganic materials 0.000 claims description 29
- 229940091250 magnesium supplement Drugs 0.000 claims description 29
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims description 19
- 102100024304 Protachykinin-1 Human genes 0.000 claims description 18
- 101800003906 Substance P Proteins 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 12
- 230000008499 blood brain barrier function Effects 0.000 claims description 9
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 9
- 230000035699 permeability Effects 0.000 claims description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 206010030113 Oedema Diseases 0.000 claims description 6
- 230000001149 cognitive effect Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- -1 GR82334 Chemical compound 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 5
- 230000000982 vasogenic effect Effects 0.000 claims description 5
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 102100029409 Neuromedin-K receptor Human genes 0.000 claims description 4
- 238000009825 accumulation Methods 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000006735 deficit Effects 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- 108010072184 MEN 10627 Proteins 0.000 claims description 3
- 206010067275 Vasogenic cerebral oedema Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 159000000003 magnesium salts Chemical class 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- CFDNUNSOUUFTQO-JYMVZIKVSA-N (1r,4s,7s,10r,13s,16r)-13-benzyl-16-(1h-indol-3-ylmethyl)-7-(2-methylpropyl)-4-(2-methylsulfanylethyl)-2,5,8,11,14,17,21-heptazabicyclo[8.8.4]docosane-3,6,9,12,15,18,20-heptone Chemical compound C([C@@H]1NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H]2CC(=O)NC[C@@H](NC1=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N2)=O)CCSC)C1=CC=CC=C1 CFDNUNSOUUFTQO-JYMVZIKVSA-N 0.000 claims description 2
- CCIWVEMVBWEMCY-RCFOMQFPSA-N (2s)-1-[(3as,4s,7as)-4-hydroxy-4-(2-methoxyphenyl)-7,7-diphenyl-1,3,3a,5,6,7a-hexahydroisoindol-2-yl]-2-(2-methoxyphenyl)propan-1-one Chemical compound COC1=CC=CC=C1[C@H](C)C(=O)N1C[C@H](C(CC[C@@]2(O)C=3C(=CC=CC=3)OC)(C=3C=CC=CC=3)C=3C=CC=CC=3)[C@H]2C1 CCIWVEMVBWEMCY-RCFOMQFPSA-N 0.000 claims description 2
- 208000034693 Laceration Diseases 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 239000001755 magnesium gluconate Substances 0.000 claims description 2
- 229960003035 magnesium gluconate Drugs 0.000 claims description 2
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 2
- UHNWOJJPXCYKCG-UHFFFAOYSA-L magnesium oxalate Chemical compound [Mg+2].[O-]C(=O)C([O-])=O UHNWOJJPXCYKCG-UHFFFAOYSA-L 0.000 claims description 2
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 2
- NXLUTEDAEFXMQR-BJKOFHAPSA-N n-[(2r,4s)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-chlorophenyl)methyl]piperidin-4-yl]quinoline-4-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2[C@@H](C[C@H](CC2)NC(=O)C=2C3=CC=CC=C3N=CC=2)CC=2C=CC(Cl)=CC=2)=C1 NXLUTEDAEFXMQR-BJKOFHAPSA-N 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 108700023329 spantide II Proteins 0.000 claims description 2
- 108700032228 spantide III Proteins 0.000 claims description 2
- AZZJAARMZMEIHY-BBKUSFMUSA-N spantide ii Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N(C(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCCNC(=O)C=1C=NC=CC=1)C(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](N)CC=1C=C(Cl)C(Cl)=CC=1)C1=CC=CC=C1 AZZJAARMZMEIHY-BBKUSFMUSA-N 0.000 claims description 2
- YBCYJDNOPAFFOW-XOAARHKISA-N win-62577 Chemical compound C1=CC=C2N(C=C3C(C=C4CC[C@@H]5[C@@H]([C@]4(C3)C)CC[C@]3([C@H]5CC[C@@]3(O)C#C)C)=N3)C3=NC2=C1 YBCYJDNOPAFFOW-XOAARHKISA-N 0.000 claims description 2
- KIPTYYXCLIQOHM-KKMBCTKYSA-N (2s)-n-[(2s,3s)-1-amino-3-methyl-1-oxopentan-2-yl]-1-[(2r)-1-[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-benzamidopropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC[C@H](C)[C@@H](C(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1N(C(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)C=2C=CC=CC=2)CCC1 KIPTYYXCLIQOHM-KKMBCTKYSA-N 0.000 claims 2
- GEMYTIALOXZOQO-IXOXMDGESA-N (2s,3s)-2-phenyl-n-[(5-propan-2-yl-2,3-dihydro-1-benzofuran-7-yl)methyl]piperidin-3-amine;dihydrochloride Chemical compound Cl.Cl.C1([C@@H]2NCCC[C@@H]2NCC=2C=3OCCC=3C=C(C=2)C(C)C)=CC=CC=C1 GEMYTIALOXZOQO-IXOXMDGESA-N 0.000 claims 1
- WSLTYZVXORBNLB-UHFFFAOYSA-N 2-benzhydryl-n-[(2-iodophenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine Chemical compound IC1=CC=CC=C1CNC1C(C(C=2C=CC=CC=2)C=2C=CC=CC=2)N2CCC1CC2 WSLTYZVXORBNLB-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108010078913 substance P (6-11) Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 11
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 9
- 208000030886 Traumatic Brain injury Diseases 0.000 description 9
- 206010048962 Brain oedema Diseases 0.000 description 7
- 206010019196 Head injury Diseases 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 5
- 229910001425 magnesium ion Inorganic materials 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 230000009529 traumatic brain injury Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 208000006752 brain edema Diseases 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000007971 neurological deficit Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 3
- 208000008457 Neurologic Manifestations Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 230000007278 cognition impairment Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- CWEISCOCKRHHOU-UJYVDGJVSA-N (2s)-n-[(2s)-1-amino-1-oxohexan-2-yl]-1-[(2r)-1-[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-benzamidopropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CCCC[C@@H](C(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1N(C(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)C=2C=CC=CC=2)CCC1 CWEISCOCKRHHOU-UJYVDGJVSA-N 0.000 description 2
- VNRJGEMERJZKLQ-UHFFFAOYSA-N 2-piperazin-1-ylacetamide Chemical compound NC(=O)CN1CCNCC1 VNRJGEMERJZKLQ-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 208000018652 Closed Head injury Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 2
- DZOJBGLFWINFBF-UMSFTDKQSA-N osanetant Chemical compound C([C@](C1)(CCCN2CCC(CC2)(N(C(C)=O)C)C=2C=CC=CC=2)C=2C=C(Cl)C(Cl)=CC=2)CCN1C(=O)C1=CC=CC=C1 DZOJBGLFWINFBF-UMSFTDKQSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- YTIHIRCOUAPRCS-YFKPBYRVSA-N (2s)-2-aminohexanamide Chemical compound CCCC[C@H](N)C(N)=O YTIHIRCOUAPRCS-YFKPBYRVSA-N 0.000 description 1
- LOLQIXVGWUZRTD-GLANSSQHSA-N (5s,8s,11s,12z)-5-amino-n-[(2s)-1-[[(2s)-3-(1h-indol-3-yl)-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]propan-2-yl]amino]-1,4-dioxobutan-2-yl]-8-(2-methylpropyl)-6,9-dioxo-1-thia-3,7,10-triazacyclotridec-12-ene-11-carboxamide Chemical compound N1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CNCS\C=C/[C@H]1C(=O)N[C@@H](CC=O)C(=O)N[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)CC1=CNC2=CC=CC=C12 LOLQIXVGWUZRTD-GLANSSQHSA-N 0.000 description 1
- BGXMXYKDFFAEKA-UHFFFAOYSA-N 1,2,3,3a,5,6,7,7a-octahydroisoindol-4-one Chemical compound O=C1CCCC2CNCC12 BGXMXYKDFFAEKA-UHFFFAOYSA-N 0.000 description 1
- MDTUWBLTRPRXBX-UHFFFAOYSA-N 1,2,4-triazol-3-one Chemical compound O=C1N=CN=N1 MDTUWBLTRPRXBX-UHFFFAOYSA-N 0.000 description 1
- KYHMFVRVHASKGM-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindol-4-ol Chemical compound OC1CCCC2CNCC12 KYHMFVRVHASKGM-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- QNLIUVLFRVYNCV-XIFFEERXSA-N 3-[1-[2-[(2r)-4-benzoyl-2-(3,4-difluorophenyl)morpholin-2-yl]ethyl]-4-phenylpiperidin-4-yl]-1,1-dimethylurea Chemical compound C([C@@](OCC1)(CCN2CCC(CC2)(NC(=O)N(C)C)C=2C=CC=CC=2)C=2C=C(F)C(F)=CC=2)N1C(=O)C1=CC=CC=C1 QNLIUVLFRVYNCV-XIFFEERXSA-N 0.000 description 1
- 150000005361 3-phenylpyridines Chemical class 0.000 description 1
- MKLQPIYLZMLAER-UHFFFAOYSA-N 4-phenylpyrimidine Chemical class C1=CC=CC=C1C1=CC=NC=N1 MKLQPIYLZMLAER-UHFFFAOYSA-N 0.000 description 1
- LVXOXXGCJHYEOS-UHFFFAOYSA-N 5-phenylpyrimidine Chemical class C1=CC=CC=C1C1=CN=CN=C1 LVXOXXGCJHYEOS-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000012184 Diffuse Brain injury Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 108010086932 R 820 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- COWAAOSLGYXWBG-UHFFFAOYSA-N ethene;piperidine Chemical group C=C.C1CCNCC1 COWAAOSLGYXWBG-UHFFFAOYSA-N 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- MVKWXCHZQUBXQB-HHHXNRCGSA-N n-[(2r)-3-(1h-indol-3-yl)-2-[[2-(4-piperidin-1-ylpiperidin-1-yl)acetyl]amino]propyl]-3-(2-methoxyphenyl)propanamide Chemical compound COC1=CC=CC=C1CCC(=O)NC[C@H](NC(=O)CN1CCC(CC1)N1CCCCC1)CC1=CNC2=CC=CC=C12 MVKWXCHZQUBXQB-HHHXNRCGSA-N 0.000 description 1
- ZSAFRVVCZQRBQS-UHFFFAOYSA-N n-benzyl-2-(4-methylphenyl)pyridine-3-carboxamide Chemical class C1=CC(C)=CC=C1C1=NC=CC=C1C(=O)NCC1=CC=CC=C1 ZSAFRVVCZQRBQS-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- HOHWYQSDLRTVDK-UHFFFAOYSA-N pyrimido[1,2-a]benzimidazole Chemical compound N1=CC=CN2C3=CC=CC=C3N=C21 HOHWYQSDLRTVDK-UHFFFAOYSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ5146A AUPQ514600A0 (en) | 2000-01-18 | 2000-01-18 | Brain injury treatment |
| PCT/AU2001/000046 WO2001052844A1 (en) | 2000-01-18 | 2001-01-18 | Brain, spinal and nerve injury treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ519990A true NZ519990A (en) | 2004-10-29 |
Family
ID=3819274
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ519990A NZ519990A (en) | 2000-01-18 | 2001-01-18 | Brain, spinal and nerve injury treatment |
| NZ534278A NZ534278A (en) | 2000-01-18 | 2001-01-18 | Brain, spinal and nerve injury treatment |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ534278A NZ534278A (en) | 2000-01-18 | 2001-01-18 | Brain, spinal and nerve injury treatment |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US6841551B2 (enExample) |
| EP (1) | EP1261335B1 (enExample) |
| JP (1) | JP4794794B2 (enExample) |
| KR (1) | KR100780119B1 (enExample) |
| CN (1) | CN1261095C (enExample) |
| AU (2) | AUPQ514600A0 (enExample) |
| BR (1) | BR0107695A (enExample) |
| CA (1) | CA2397723C (enExample) |
| CZ (1) | CZ20022804A3 (enExample) |
| DE (1) | DE60139244D1 (enExample) |
| HR (1) | HRP20020593B1 (enExample) |
| HU (1) | HUP0301920A3 (enExample) |
| IL (2) | IL150548A0 (enExample) |
| MX (1) | MXPA02007004A (enExample) |
| NO (1) | NO329320B1 (enExample) |
| NZ (2) | NZ519990A (enExample) |
| RU (1) | RU2276996C2 (enExample) |
| WO (1) | WO2001052844A1 (enExample) |
| YU (1) | YU54702A (enExample) |
| ZA (1) | ZA200205715B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
| US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| KR101227626B1 (ko) | 2003-01-28 | 2013-02-01 | 아이언우드 파마슈티컬스, 인코포레이티드 | 위장병 치료 방법 및 위장병 치료용 조성물 |
| GB0410215D0 (en) * | 2004-05-07 | 2004-06-09 | Lescroart Pol | Nerve damage |
| JP2008514612A (ja) * | 2004-09-23 | 2008-05-08 | ミシャロウ、アレクサンダー | 対抗適応を誘発することにより神経伝達物質系を調節する方法 |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| CN101128189A (zh) | 2005-02-25 | 2008-02-20 | 弗·哈夫曼-拉罗切有限公司 | 药物物质分散性改善的片剂 |
| WO2006110118A1 (fr) * | 2005-04-15 | 2006-10-19 | Victor Pavlovich Kutnyak | Produit cytoprotecteur |
| US20060239921A1 (en) | 2005-04-26 | 2006-10-26 | Novadaq Technologies Inc. | Real time vascular imaging during solid organ transplant |
| WO2006116634A2 (en) | 2005-04-26 | 2006-11-02 | Novadaq Technologies, Inc. | Method and apparatus for vasculature visualization with applications in neurosurgery and neurology |
| US10231624B2 (en) * | 2005-08-10 | 2019-03-19 | Nov Adaq Technologies Ulc | Intra-operative head and neck nerve mapping |
| US20070122344A1 (en) * | 2005-09-02 | 2007-05-31 | University Of Rochester Medical Center Office Of Technology Transfer | Intraoperative determination of nerve location |
| US20070154448A1 (en) * | 2005-11-22 | 2007-07-05 | Ted Reid | Methods and compositions using Substance P to promote wound healing |
| US8945623B2 (en) * | 2006-05-03 | 2015-02-03 | Warsaw Orthopedic, Inc. | Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use |
| US20080161744A1 (en) * | 2006-09-07 | 2008-07-03 | University Of Rochester Medical Center | Pre-And Intra-Operative Localization of Penile Sentinel Nodes |
| US20080241121A1 (en) * | 2007-04-02 | 2008-10-02 | Daniela Salvemini | Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain |
| US20100086543A1 (en) * | 2007-04-02 | 2010-04-08 | Saint Louis University | Compositions and methods for treating conditions associated with ceramide biosynthesis |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| MX2010000724A (es) * | 2007-07-19 | 2010-06-02 | Adelaide Res & Innovation Pty | Metodo para reducir presion intracraneal. |
| US8406860B2 (en) | 2008-01-25 | 2013-03-26 | Novadaq Technologies Inc. | Method for evaluating blush in myocardial tissue |
| US10219742B2 (en) | 2008-04-14 | 2019-03-05 | Novadaq Technologies ULC | Locating and analyzing perforator flaps for plastic and reconstructive surgery |
| US20090263507A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use |
| EP2285421B1 (en) | 2008-05-02 | 2018-04-11 | Novadaq Technologies ULC | Methods for production and use of substance-loaded erythrocytes for observation and treatment of microvascular hemodynamics |
| CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CA2748607A1 (en) | 2008-12-31 | 2010-07-08 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US8852566B2 (en) * | 2009-03-26 | 2014-10-07 | Warsaw Orthopedic, Inc. | Compositions and methods for preferential distribution of active agents to injury sites |
| US10492671B2 (en) | 2009-05-08 | 2019-12-03 | Novadaq Technologies ULC | Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| WO2012074043A1 (ja) * | 2010-12-03 | 2012-06-07 | 国立大学法人 岡山大学 | 外傷性神経障害治療剤 |
| WO2012125020A1 (en) * | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
| WO2013190391A2 (en) | 2012-06-21 | 2013-12-27 | Novadaq Technologies Inc. | Quantification and analysis of angiography and perfusion |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| WO2014029983A1 (en) | 2012-08-21 | 2014-02-27 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| ES2735992T3 (es) | 2013-04-12 | 2019-12-23 | Ardelyx Inc | Compuestos de unión a NHE3 y procedimientos para inhibir el transporte de fosfatos |
| CN105764916B (zh) | 2013-06-05 | 2021-05-18 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
| HK1221637A1 (zh) * | 2013-07-02 | 2017-06-09 | 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） | 用於预防和/或治疗ii型慢性创伤性脑病的方法 |
| EP3016658A4 (en) * | 2013-07-02 | 2017-03-15 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-iv |
| EP3016659A4 (en) * | 2013-07-02 | 2017-03-15 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-iii |
| JP2016523866A (ja) * | 2013-07-02 | 2016-08-12 | ユーストラリス ファーマシューティカルズ リミテッド （トレーディング アズ プレススラ ニューロ） | 慢性外傷性脳障害ｉを予防及び／又は治療する方法 |
| EP3201607B1 (en) | 2014-09-29 | 2020-12-30 | Novadaq Technologies ULC | Imaging a target fluorophore in a biological material in the presence of autofluorescence |
| CA2963450A1 (en) | 2014-10-09 | 2016-04-14 | Novadaq Technologies Inc. | Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography |
| JP7292207B2 (ja) | 2017-01-09 | 2023-06-16 | アルデリックス， インコーポレイテッド | 消化管障害を処置するために有用な化合物 |
| EA201991676A1 (ru) | 2017-01-09 | 2020-01-30 | Арделикс, Инк. | Ингибиторы nhe-опосредованного антипорта |
| JP6931705B2 (ja) | 2017-02-10 | 2021-09-08 | ノバダック テクノロジーズ ユーエルシー | オープンフィールドハンドヘルド蛍光イメージングシステムおよび方法 |
| KR20220050956A (ko) * | 2019-08-23 | 2022-04-25 | 유스트랄리스 파마슈티칼스 리미티드 (트레이딩 애즈 프레스수라 뉴로) | 치료 방법 및 이의 용도 |
| WO2021202286A1 (en) * | 2020-03-30 | 2021-10-07 | Dignify Therapeutics, Llc | Compositions and methods for treating autonomic dysreflexia |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4481139A (en) * | 1983-04-13 | 1984-11-06 | Board Of Regents, The University Of Texas System | Peptide antagonists of substance P |
| US4985896A (en) * | 1985-03-29 | 1991-01-15 | Canon Kabushiki Kaisha | Laser driving device |
| GB8929070D0 (en) * | 1989-12-22 | 1990-02-28 | Fujisawa Pharmaceutical Co | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
| US4981744A (en) * | 1990-04-24 | 1991-01-01 | Swank Michael W | Non-planar expandable honeycomb structure |
| EP0655055B1 (en) * | 1992-08-13 | 2000-11-29 | Warner-Lambert Company | Tachykinin antagonists |
| US5610165A (en) * | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
| US5744482A (en) * | 1994-10-05 | 1998-04-28 | Eli Lilly And Company | Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine |
| US5998444A (en) * | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
| IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
| WO1996024353A1 (en) * | 1995-02-10 | 1996-08-15 | Eli Lilly And Company | Methods of treating or preventing psychiatric disorders |
| US5795894A (en) * | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
| US5990125A (en) | 1996-01-19 | 1999-11-23 | Pfizer Inc. | NK-1 receptor antagonists for the treatment of cancer |
| WO1997038701A1 (en) * | 1996-04-12 | 1997-10-23 | Neotech Medical Innovations In | Composition and method for the treatment of premenstrual syndrome |
| US5977104A (en) * | 1996-12-02 | 1999-11-02 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating bipolar disorders |
| AU749976B2 (en) * | 1997-08-28 | 2002-07-04 | Merck & Co., Inc. | Method for treating premenstrual or late luteal phase syndrome |
| GB9812662D0 (en) * | 1998-06-11 | 1998-08-12 | Merck Sharp & Dohme | Therapeutic use |
| DE60045564D1 (de) * | 1999-02-24 | 2011-03-03 | Hoffmann La Roche | 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten |
| CN1131212C (zh) | 1999-02-24 | 2003-12-17 | 弗·哈夫曼-拉罗切有限公司 | 苯基－和吡啶基衍生物 |
| CN1134417C (zh) | 1999-02-24 | 2004-01-14 | 弗·哈夫曼-拉罗切有限公司 | 3-苯基吡啶衍生物及其作为nk-1受体拮抗剂的应用 |
| US6291465B1 (en) | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
| JO2308B1 (en) | 1999-05-31 | 2005-09-12 | اف. هوفمان- لاروش أيه جي | Derivatives of phenylpyrmidine |
| TW550258B (en) | 1999-05-31 | 2003-09-01 | Hoffmann La Roche | 4-phenyl-pyrimidine derivatives |
| GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
| AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
| US6479433B1 (en) * | 2000-10-02 | 2002-11-12 | Smithers-Oasis Company | Polyurethane foam composites for grower applications and related methods |
-
2000
- 2000-01-18 AU AUPQ5146A patent/AUPQ514600A0/en not_active Abandoned
-
2001
- 2001-01-18 US US10/181,323 patent/US6841551B2/en not_active Expired - Fee Related
- 2001-01-18 RU RU2002121640/15A patent/RU2276996C2/ru not_active IP Right Cessation
- 2001-01-18 KR KR1020027009218A patent/KR100780119B1/ko not_active Expired - Fee Related
- 2001-01-18 DE DE60139244T patent/DE60139244D1/de not_active Expired - Fee Related
- 2001-01-18 CN CNB018037208A patent/CN1261095C/zh not_active Expired - Fee Related
- 2001-01-18 YU YU54702A patent/YU54702A/sh unknown
- 2001-01-18 BR BR0107695-7A patent/BR0107695A/pt not_active IP Right Cessation
- 2001-01-18 MX MXPA02007004A patent/MXPA02007004A/es active IP Right Grant
- 2001-01-18 CA CA2397723A patent/CA2397723C/en not_active Expired - Fee Related
- 2001-01-18 NZ NZ519990A patent/NZ519990A/en not_active IP Right Cessation
- 2001-01-18 WO PCT/AU2001/000046 patent/WO2001052844A1/en not_active Ceased
- 2001-01-18 HR HR20020593A patent/HRP20020593B1/xx not_active IP Right Cessation
- 2001-01-18 EP EP01901048A patent/EP1261335B1/en not_active Expired - Lifetime
- 2001-01-18 NZ NZ534278A patent/NZ534278A/en not_active IP Right Cessation
- 2001-01-18 IL IL15054801A patent/IL150548A0/xx unknown
- 2001-01-18 JP JP2001552892A patent/JP4794794B2/ja not_active Expired - Fee Related
- 2001-01-18 AU AU26560/01A patent/AU782799B2/en not_active Expired
- 2001-01-18 HU HU0301920A patent/HUP0301920A3/hu unknown
- 2001-01-18 CZ CZ20022804A patent/CZ20022804A3/cs unknown
-
2002
- 2002-07-02 IL IL150548A patent/IL150548A/en not_active IP Right Cessation
- 2002-07-17 ZA ZA200205715A patent/ZA200205715B/en unknown
- 2002-07-17 NO NO20023423A patent/NO329320B1/no not_active IP Right Cessation
-
2004
- 2004-12-21 US US11/017,978 patent/US20050107380A1/en not_active Abandoned
-
2009
- 2009-06-01 US US12/475,627 patent/US9186404B2/en not_active Expired - Lifetime
-
2015
- 2015-10-13 US US14/882,084 patent/US20160030474A1/en not_active Abandoned
-
2017
- 2017-09-25 US US15/714,819 patent/US10201568B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ519990A (en) | Brain, spinal and nerve injury treatment | |
| RU2244558C2 (ru) | Анестетическая композиция, включающая антагонист nmda и альфа-2 адренергический агонист | |
| Rupniak et al. | Antinociceptive activity of NK1 receptor antagonists: non‐specific effects of racemic RP67580 | |
| Haley et al. | Electrophysiological evidence for a role of bradykinin in chemical nociception in the rat | |
| KR20030040201A (ko) | 급성 통증, 만성 통증 및/또는 신경병성 통증 및 편두통을치료하기 위한 약학 조성물 | |
| Melis et al. | Penile erection and yawning induced by paraventricular NMDA injection in male rats are mediated by oxytocin | |
| Negri et al. | Behavioural effects of deltorphins in rats | |
| Wilker | Theories related to physical dependence | |
| CLAYTON et al. | The pharmacological properties of the novel selective 5‐HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat | |
| Coram et al. | The antihypertensive effect of a selective central muscarinic cholinergic antagonist: N‐(4‐diethylamino‐2‐butynyl)‐succinimide | |
| Feuerstein et al. | Effect of dermorphin and morphine on the sympathetic and cardiovascular system of the pithed rat | |
| Caner et al. | Systemic administration of mexiletine for attenuation of cerebral vasospasm following experimental subarachnoid haemorrhage | |
| Major et al. | Effects of quinapril, a new angiotensin-converting enzyme inhibitor, on vasoconstrictor activity in the isolated, perfused mesenteric vasculature of hypertensive rats. | |
| HK1054872B (en) | Brain, spinal and nerve injury treatment | |
| PL203468B1 (pl) | Preparat do do zylnego lub domi esniowego leczenia uszkodzenia mózgu, rdzenia kr egowego i nerwów | |
| US20050031608A1 (en) | Modified alpha-neurotoxins as painkillers | |
| Shah et al. | Age-dependent alterations in Na+, K+-ATPase activity in the central nervous system of spontaneously hypertensive rats: relationship to the development of high blood pressure | |
| Abrahams et al. | Stimulant effect of human gamma globulin on smooth muscle preparations | |
| Miller et al. | Cholecystokinin (CCK) inhibits excitation of pyramidal neurons by non-peptide, but not peptide, opioid agonists in the rat hippocampus | |
| Ansohn | Abstinence-Like Syndrome in the Rat Following Chronic Treatment with d-Phenylalanine and d-Leucine | |
| Rahman | Development of opiod analgesic systems in the rat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 18 JAN 2021 BY CPA GLOBAL Effective date: 20140116 |
|
| EXPY | Patent expired |